Arrythmia clinical trials

Explore recruiting arrythmia clinical trials.

Recruiting arrythmia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Arrythmia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A blinded randomized study of ephedrine 0.15 mg/kg for reducing onset time of rocuronium 0.6 mg/kg in elderly patients (≥ 80 years)

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A PHASE 2A, INVESTIGATOR AND SUBJECT BLINDED, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA

France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 2, DOUBLE-BLIND, REPEAT-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CRD-4730 IN PARTICIPANTS WITH CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA

Netherlands, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK)

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

LOW-DOSE DOBUTAMINE INFUSION AND SINGLE-DOSE TOCILIZUMAB IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH HIGH RISK OF CARDIOGENIC SHOCK DEVELOPMENT (DOBERMANN) - A 2X2 MULTIFACTORIAL, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Arrythmia trials by city

Arrythmia in Toronto Arrythmia in Vancouver Arrythmia in Montreal Arrythmia in Calgary Arrythmia in Edmonton Arrythmia in Ottawa Arrythmia in Winnipeg Arrythmia in Quebec City Arrythmia in Hamilton Arrythmia in Kitchener Arrythmia in London Arrythmia in Halifax Arrythmia in New York Arrythmia in Los Angeles Arrythmia in Chicago Arrythmia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease